全文获取类型
收费全文 | 580篇 |
免费 | 21篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 6篇 |
妇产科学 | 5篇 |
基础医学 | 40篇 |
口腔科学 | 6篇 |
临床医学 | 36篇 |
内科学 | 198篇 |
皮肤病学 | 1篇 |
神经病学 | 123篇 |
特种医学 | 12篇 |
外科学 | 90篇 |
综合类 | 3篇 |
预防医学 | 15篇 |
眼科学 | 5篇 |
药学 | 43篇 |
肿瘤学 | 20篇 |
出版年
2024年 | 2篇 |
2023年 | 2篇 |
2022年 | 5篇 |
2021年 | 8篇 |
2020年 | 4篇 |
2019年 | 5篇 |
2018年 | 8篇 |
2017年 | 8篇 |
2016年 | 6篇 |
2015年 | 8篇 |
2014年 | 12篇 |
2013年 | 25篇 |
2012年 | 58篇 |
2011年 | 38篇 |
2010年 | 16篇 |
2009年 | 21篇 |
2008年 | 38篇 |
2007年 | 28篇 |
2006年 | 22篇 |
2005年 | 24篇 |
2004年 | 28篇 |
2003年 | 14篇 |
2002年 | 25篇 |
2001年 | 16篇 |
2000年 | 17篇 |
1999年 | 9篇 |
1998年 | 5篇 |
1997年 | 3篇 |
1996年 | 5篇 |
1994年 | 6篇 |
1992年 | 13篇 |
1991年 | 19篇 |
1990年 | 8篇 |
1989年 | 12篇 |
1988年 | 9篇 |
1987年 | 2篇 |
1986年 | 15篇 |
1985年 | 17篇 |
1984年 | 15篇 |
1983年 | 6篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1979年 | 3篇 |
1978年 | 4篇 |
1976年 | 1篇 |
1974年 | 2篇 |
1971年 | 1篇 |
1970年 | 1篇 |
1968年 | 1篇 |
1967年 | 2篇 |
排序方式: 共有604条查询结果,搜索用时 15 毫秒
21.
Umberto Volpe Hania Amin Olatunde O. Ayinde Alistair Burns Wai Chi Chan Renaud David Slavica Djukic Dejanovic Gorica Djokic Defne Eraslan Giulia A.L. Fischer Patricia Gracia-García Syed Usman Hamdani Changsu Han Hussain Jafri Roy A. Kallivayalil Roderick Leonard Kriekaart Ee Heok Kua Linda C.W. Lam Dusica Lecic-Tosevski Iracema Leroi Antonio Lobo Adriana Mihai Fareed Aslam Minhas Heena Mistry Afolakemi T. Ogundele Marcel G.M. Olde Rikkert Javier Olivera Claudia Palumbo Angela Parker Bojana Pejuskovic Florian Riese Philippe Robert Maya Semrau Gabriela Stoppe Sanu Sudhakar Andreea Raluca Tirintica Sehrish Tofique Chris Tsoi Lucas Wolski Irem Yalug Huali Wang Xin Yu Norman Sartorius 《International journal of geriatric psychiatry》2020,35(2):163-173
22.
P B Dobrin J Golan J Fareed B Blakeman F N Littoy 《The Journal of cardiovascular surgery》1992,33(6):705-709
Several clinical studies have shown that pharmacologic inhibition of platelets can increase the patency of vascular grafts, but only if platelet-inhibition is initiated before surgery. This study was performed to compare the efficacy of pre- vs postoperative platelet-inhibition on the development of intimal hyperplasia in canine autogenous vein grafts. Reversed femoral veins were used to bypass the ligated femoral arteries in 15 dogs. End-to-side anastomoses were constructed. Eleven dogs were treated with aspirin (325 mg QD) and dipyridamole (25 mg BID). In six dogs treatment was begun 48 hours preoperatively and continued for 3 months. In five other dogs treatment was begun 48 hours after surgery and was continued for 3 months. In 4 control dogs no antiplatelet treatment was given. Excision of the vein grafts 3 months after surgery disclosed reduced intimal hyperplasia (p < 0.05) in the grafts excised from all of the treated animals as compared with those obtained from the control animals. However, there was no difference in intimal hyperplasia observed in the dogs treated both pre- and postoperatively (11 grafts) as compared with those treated only postoperatively (9 grafts). These data demonstrate that it is not necessary to begin antiplatelet therapy preoperatively in order to inhibit intimal hyperplasia. They also suggest that preoperative antiplatelet therapy may improve early graft patency by directly preventing thrombosis, not by inhibiting the development of intimal hyperplasia. 相似文献
23.
Apoptosis as a form of cell death in intracerebral hemorrhage 总被引:73,自引:0,他引:73
Qureshi AI Suri MF Ostrow PT Kim SH Ali Z Shatla AA Guterman LR Hopkins LN 《Neurosurgery》2003,52(5):1041-7; discussion 1047-8
OBJECTIVE: The goals of this study were to identify and quantify the presence of programmed cell death (apoptosis) in intracerebral hemorrhage (ICH) among human subjects. Recent evidence from laboratory models suggests that cell death in the perihematoma region may involve apoptosis. METHODS: Retrospective clinical and histological analyses were performed for patients with spontaneous ICH who underwent surgical evacuation. Quantification of apoptotic cells was performed in sections obtained from the perihematoma region from 12 patients with ICH and stained with the terminal deoxynucleotidyl transferase-mediated deoxyuridine 5-triphosphate nick-end labeling method. Necrosis was identified on the basis of morphological criteria, using hematoxylin and eosin staining. RESULTS: Evidence of apoptosis was present in surgical specimens obtained from 10 of the 12 patients. The mean number of apoptotic cells in the perihematoma region in each patient specimen was 38% (range, 0-90%). For five patients, more than one-half of the total cells observed were apoptotic. Apoptosis was observed in specimens obtained within 1 day, 2 days, and 5 days after the onset of symptoms. No terminal deoxynucleotidyl transferase-mediated deoxyuridine 5-triphosphate nick-end labeling-positive cells were observed in specimens from the two patients with cerebellar hematomas. The mean proportion of necrotic cells in the perihematoma region in each patient specimen was 25% (range, 0-100%). There was a prominent excess of apoptotic cells, in comparison with necrotic cells, for 6 of the 12 patients who underwent hematoma evacuation. For five other patients, similar proportions of apoptotic and necrotic cells were observed. Necrosis was the predominant finding for only one patient, who underwent late surgical evacuation on Day 5. CONCLUSION: These observations suggest that apoptosis represents a prominent form of cell death associated with ICH in the perihematoma region. Further studies are required to define the mediators of apoptosis in ICH. 相似文献
24.
Prognostic significance of hypernatremia and hyponatremia among patients with aneurysmal subarachnoid hemorrhage 总被引:4,自引:0,他引:4
Qureshi AI Suri MF Sung GY Straw RN Yahia AM Saad M Guterman LR Hopkins LN 《Neurosurgery》2002,50(4):749-55; discussion 755-6
OBJECTIVE: Abnormal serum sodium levels (hyponatremia and hypernatremia) are frequently observed during the acute period after aneurysmal subarachnoid hemorrhage (SAH) and may worsen cerebral edema and mass effect. We performed this study to determine the prognostic significance of serum sodium concentration abnormalities. METHODS: We analyzed prospectively collected data for the placebo treatment group in a clinical trial conducted at 54 neurosurgical centers in North America. The presence of hypernatremia (serum sodium concentration of >145 mmol/L) and hyponatremia (serum sodium concentration of <135 mmol/L) was determined with serum sodium measurements obtained at admission and 3, 6, and 9 days after SAH. The effects of hypernatremia and hyponatremia on the risk of symptomatic vasospasm and on 3-month outcomes were analyzed after adjustment for the following potential confounding factors: age, sex, preexisting hypertension, admission Glasgow Coma Scale score, initial mean arterial pressure, subarachnoid clot thickness, intraventricular blood or intraparenchymal hematoma, ventricular dilation, and aneurysm size and location. RESULTS: Of 298 patients in the analysis, 58 (19%) developed hypernatremia and 88 (30%) developed hyponatremia. Hypernatremia was significantly associated with poor outcomes (odds ratio, 2.7; 95% confidence interval, 1.2-6.1). A positive correlation was observed between the highest sodium values recorded and Glasgow Outcome Scale scores at 3 months (P < 0.0001 by analysis of variance). Hyponatremia was not associated with 3-month outcomes (odds ratio, 1.9; 95% confidence interval, 0.9-4.3). Neither hypernatremia nor hyponatremia was associated with the risk of symptomatic vasospasm. CONCLUSION: Hyponatremia seems to be more common than hypernatremia after SAH. However, hypernatremia after SAH is independently associated with poor outcomes, and this association is independent of previously identified outcome predictors, including age and admission Glasgow Coma Scale scores. Further studies are needed to define the underlying mechanism of this association. 相似文献
25.
Walzer M Lorens S Hejna M Fareed J Hanin I Cornelli U Lee JM 《European journal of pharmacology》2002,445(3):211-220
Previous studies have shown different roles for proteoglycans and glycosaminoglycans (GAGs) in Alzheimer's disease (AD) neuropathology. Using a rat model of beta-amyloid induced neuropathology, we tested whether low molecular weight glycosaminoglycans (Certoparin and C6) could be useful as preventative agents and/or as a potential therapeutic treatment for AD. Chronic subcutaneous low molecular weight glycosaminoglycan injections beginning either before or after an intra-amygdaloid beta-amyloid-(25-35) injection blocked abnormal intracellular tau changes and reactive astrocytosis but did not affect beta-amyloid's aggregation state. Also, low molecular weight glycosaminoglycan injections beginning 1 day prior to sacrifice did not block the effects of beta-amyloid nor did injections of a disaccharide, suggesting chronic low molecular weight glycosaminoglycan treatment is needed to block the effects of beta-amyloid. Furthermore, these data indicate that there is a molecular weight range of active low molecular weight glycosaminoglycans in this model; and supports the investigation of low molecular weight glycosaminoglycans as a preventative and/or therapeutic treatment of beta-amyloid induced neuropathology. 相似文献
26.
Walenga JM Jeske WP Samama MM Frapaise FX Bick RL Fareed J 《Expert opinion on investigational drugs》2002,11(3):397-407
Fondaparinux (Arixtra, Sanofi-Synthélabo/Organon) is the first of a new class of antithrombotic agents distinct from low molecular weight heparins (LMWHs) and heparin. It is a chemically synthetic pentasaccharide mimicking the site of heparin that binds to antithrombin III (AT). It exhibits only factor (F) Xa (FXa) inhibitor activity via binding to AT, which in turn inhibits thrombin generation. In contrast to heparin and LMWH, plasma anti-Xa activity corresponds directly to levels of fondaparinux. It does not release tissue factor pathway inhibitor (TFPI). There is nearly complete bioavailability by the sc. route, rapid onset of action, a prolonged half-life in both iv. and sc. (14 - 20 h) dosing regimens and no metabolism preceding renal excretion. Phase IIb clinical studies have identified a dose of 2.5 mg once-daily for prophylaxis of venous thrombosis. Four Phase III studies (n > 7000) have demonstrated a combined 50% relative risk reduction of venous thromboembolic events in orthopaedic surgery patients in comparison to the LMWH, enoxaparin. Haemmorrhagic complications for fondaparinux were either comparable to or higher than those for LMWH. The activated partial thromboplastin time (aPTT) is not affected by fondaparinux. At present, laboratory monitoring is not recommended. Clinical trials for treatment of established thrombosis, coronary syndromes and adjunct to thrombolytic therapy are in progress. 相似文献
27.
Ma Q Schultz C Neville B Jeske W Hoppensteadt D Cornelli U Lee J Lorens S Hanin I Fareed J 《Thrombosis research》2003,112(4):249-255
The heparin-derived oligosaccharide C3 (C3) is currently underdevelopment for the prevention and treatment of vascular dementia and senile dementia of Alzheimer's type. C3 exhibits a molecular weight of 2200-2500 Da with a narrow distribution. The objective of the present study was to assess the pharmacodynamics and pharmacokinetics of C3 in non-human primates. C3 was administered as an intravenous or subcutaneous bolus dose of 1.0 or 2.5 mg/kg. Anti-factor Xa activity, Heptest clotting time and activated partial thromboplastin time were measured to determine pharmacodynamic effects of C3 in plasma. The pharmacokinetics of C3 was primarily characterized by measuring plasma anti-factor Xa activity as a surrogate marker. The rate of absorption and elimination of C3 after administration did not change with increasing dose. The volume of distribution of C3 was small, reflecting a major distribution inside the intravascular space (110-130 ml/kg), and was independent of dose. The total clearance (16.0-21.0 ml/h/kg) and half-life (4-6 h) of C3 were also dose-independent. Within the observed dose range, a 2.5 times of the C3 dose resulted in an area under the plasma concentration-time curve that was approximately 16-27% greater than expected on the basis of linear disposition. These differences could be attributed to the endogenous release of tissue factor pathway inhibitor (TFPI) by C3 at higher doses, which is associated with the vascular effects of C3. 相似文献
28.
29.
P Bacher D Welzel O Iqbal D Hoppensteadt D Callas J M Walenga J Fareed 《Thrombosis research》1992,66(2-3):151-158
Since the beginning of the clinical use of low molecular weight (LMW) heparins their thrombolytic or profibrinolytic potency has been a matter of controversial discussions. Regarding this problem, the aim of our study was to test a LMW-heparin (Sandoparin) in an in vivo model comparing its lytic activity to unfractionated heparin and urokinase at different doses. For this purpose a newly developed short-term rabbit jugular vein clot lysis model was developed. Urokinase infused at doses of 3300, 6600 and 10,000 U/kg to control animals for one hour showed a clear dose-dependent clot lysis. Test animals were injected with a bolus of 0.5 mg/kg of LMW-heparin followed by a constant infusion of either 0.5, 1.0 or 2.0 mg/kg for one hour. A similar dose-dependent effect was observed for LMW-heparin as for urokinase. Unfractionated heparin did not exhibit a dose-dependent lytic activity in this model. No lysis was found in rabbits treated with saline. These findings suggest that the LMW-heparin tested exhibits a dose-dependent in vivo lytic activity which can be compared to clinically effective doses of urokinase, and that this activity is not present with unfractionated heparin. 相似文献
30.
Coetzee D Hilderbrand K Boulle A Draper B Abdullah F Goemaere E 《Bulletin of the World Health Organization》2005,83(7):489-494
OBJECTIVE: The aim of this study was to estimate the field efficacy of the first routine programme for the prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) initiated in South Africa, in the subdistrict of Khayelitsha. METHODS: A consecutive sample of 658 mother-infant pairs, identified from the PMTCT register from 1 March to 30 November 2003, were identified for enrolment in this study. Details of the regimen received were established and HIV status of the infants at between 6 and 10 weeks of age was determined by qualitative DNA polymerase chain reaction. Zidovudine (AZT) was provided antenatally from week 34 of gestation and during labour. Infant formula milk was-offered to mothers who chose not to breastfeed. The protocol was amended in July 2003 such that women who had received < 2 weeks of treatment with AZT were given a single dose of nevirapine (NVP) at the onset of labour, and the infant received a weight-adjusted dose of NVP within 72 h of delivery. RESULTS: Of the 535 mother-infant pairs (81%) eventually included in the study, 410 (77%) received an effective PMTCT intervention according to the protocol. The rate of transmission of HIV from mother to child was 8.8% (95% confidence interval (CI), 6.2-10.9). A maternal age of > 25 years was the only significant independent risk factor for transmission (odds ratio, 2.12; 95% CI, 1.14-4.07). CONCLUSION: The results of this study demonstrate the feasibility and effectiveness of a large-scale PMTCT programme in an urban public-sector setting. 相似文献